189 related articles for article (PubMed ID: 24109191)
21. Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study.
Fujishima H; Hasunuma T; Kawakita T; Sekiya T; Gomes P; Hollander DA
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1621-1626. PubMed ID: 32501774
[No Abstract] [Full Text] [Related]
22. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
Greiner JV; Minno G
Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
[TBL] [Abstract][Full Text] [Related]
23. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.
Abelson MB; Kaplan AP
Clin Ther; 2002 Mar; 24(3):445-56. PubMed ID: 11952027
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
Abelson MB; Welch DL
Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study.
Finegold I; Granet DB; D'Arienzo PA; Epstein AB
Clin Ther; 2006 Oct; 28(10):1630-8. PubMed ID: 17157118
[TBL] [Abstract][Full Text] [Related]
27. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Fujishima H; Ohashi Y; Takamura E
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
[TBL] [Abstract][Full Text] [Related]
29. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
Abelson MB; Spitalny L
Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
Abelson MB
Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
[TBL] [Abstract][Full Text] [Related]
31. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears.
Abelson MB; Pratt S; Mussoline JE; Townsend D
Clin Ther; 2003 Jul; 25(7):2070-84. PubMed ID: 12946551
[TBL] [Abstract][Full Text] [Related]
32. Alcaftadine for the prevention of itching associated with allergic conjunctivitis.
Mahvan TD; Buckley WA; Hornecker JR
Ann Pharmacother; 2012; 46(7-8):1025-32. PubMed ID: 22811343
[TBL] [Abstract][Full Text] [Related]
33. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
[TBL] [Abstract][Full Text] [Related]
34. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
35. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model.
Meier EJ; Torkildsen GL; Gomes PJ; Jasek MC
Clin Ophthalmol; 2018; 12():2617-2628. PubMed ID: 30587908
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
[TBL] [Abstract][Full Text] [Related]
38. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
39. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis.
Ono SJ; Lane K
Drug Des Devel Ther; 2011 Feb; 5():77-84. PubMed ID: 21340041
[TBL] [Abstract][Full Text] [Related]
40. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]